VPS35 Antibody

What is VPS35 and why is it significant in research?

VPS35 (vacuolar protein sorting 35 homolog) is a critical component of the retromer complex involved in endosomal protein sorting pathways. This protein serves as the core of the retromer complex and mediates retrograde transport of proteins from endosomes to the trans-Golgi network . Its significance stems from its direct link to neurodegenerative disorders - the D620N mutation in the VPS35 gene has been associated with type 17 Parkinson's Disease progression . Additionally, down-regulation of VPS35 has been implicated in Alzheimer's disease pathogenesis through endosome dysregulation .

What are the key specifications to consider when selecting a VPS35 antibody?

When selecting a VPS35 antibody, researchers should consider several critical specifications:

• Reactivity Profile: Confirm species reactivity matches your experimental model. Available antibodies show reactivity with human, mouse, and rat samples, with some predicted to react with bovine models based on sequence homology .

• Molecular Weight Recognition: VPS35 has a calculated molecular weight of 92 kDa but is typically observed between 80-92 kDa on Western blots .

• Antibody Type: Consider whether polyclonal (offering broader epitope recognition) or monoclonal (providing higher specificity) is appropriate for your application .

• Validation Status: Prioritize antibodies validated in knockout systems, which demonstrates specificity when the antibody detects the target in wild-type but not in knockout samples .

• Application Compatibility: Select antibodies validated for your specific application (WB, IHC, IF/ICC, IP, or CoIP) .

How does VPS35 function in cellular pathways?

VPS35 functions as a central component of the retromer complex, which is essential for endosomal protein trafficking. This complex facilitates the retrograde transport of cargo proteins from endosomes to the trans-Golgi network, preventing their degradation in lysosomes . Research demonstrates that VPS35 interacts directly with other retromer components, particularly VPS26 and VPS29, to form the recognition core of this complex .

In neuronal cells, VPS35 downregulation significantly disrupts the stability of the entire retromer complex. Studies show that silencing VPS35 (~70% decrease) results in corresponding decreases in VPS26 and VPS29 levels, indicating the interdependence of these components . This disruption leads to altered APP processing and increased Aβ1-40 peptide levels, potentially explaining the link between VPS35 dysfunction and neurodegenerative disorders .

What applications are most commonly used with VPS35 antibodies?

VPS35 antibodies have been validated for multiple applications, with the following being most common:

The antibody selection should be tailored to the specific application, as performance varies among different applications . For example, an antibody that performs well in Western blot may not necessarily show high performance in immunofluorescence.

What are the criteria for validating a high-performing VPS35 antibody?

Validation criteria for high-performing VPS35 antibodies differ based on the intended application:

• Western Blot: A high-quality antibody specifically detects the target protein in wild-type samples but shows no band in knockout lysates .

• Immunoprecipitation: The antibody should immunocapture at least 10% of the starting material of the target protein .

• Immunofluorescence: The antibody should generate a fluorescent signal that is at least 1.5-fold higher in wild-type cells compared to knockout cells .

Standardized validation approaches typically employ knockout cell lines (such as HAP1 VPS35 KO) compared with isogenic parental controls to minimize experimental variables . The use of standardized protocols ensures reliable comparison between different antibodies.

How should researchers optimize Western blot protocols for VPS35 detection?

For optimal Western blot detection of VPS35:

• Sample Preparation: Collect cells in RIPA buffer (25mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitor cocktail .

• Protein Extraction: Briefly sonicate lysates and incubate for 30 minutes on ice, then centrifuge at ~110,000 x g for 15 minutes at 4°C .

• Antibody Dilution: Start with the recommended range (1:5000-1:50000), but titrate to optimize for your specific sample type .

• Expected Band Size: Look for bands between 80-92 kDa, which is the observed molecular weight range for VPS35 .

• Controls: Include positive controls (HepG2, A549, HAP1, or HEK-293 cells) and, if possible, a knockout control to confirm specificity .

• Storage Considerations: Store antibodies at -20°C, where they remain stable for one year after shipment. Aliquoting is usually unnecessary for -20°C storage .

How can researchers design experiments to investigate VPS35's role in neurodegenerative disorders?

Designing experiments to investigate VPS35's role in neurodegenerative disorders requires a multi-faceted approach:

• VPS35 Silencing Models: Use siRNA targeting VPS35 in neuronal cell lines such as N2A APPswe cells. After confirming efficiency of silencing (~70% decrease in protein levels is achievable), measure effects on:

  • Retromer core components (VPS26, VPS29) using Western blot

  • APP processing and Aβ peptide production

  • Autophagy markers like LC3

• Mutation Models: Create cellular models expressing the D620N mutation associated with Parkinson's disease to study:

  • Protein trafficking alterations

  • Effects on retromer complex formation

  • Downstream consequences on cellular pathways

• Co-immunoprecipitation Studies: Use VPS35 antibodies with IP capabilities to investigate:

  • Protein-protein interactions within the retromer complex

  • Altered binding patterns in disease models

  • Novel interaction partners in neuronal cells

• Imaging Approaches: Employ immunofluorescence with validated antibodies to:

  • Visualize VPS35 localization in normal vs. diseased states

  • Monitor endosomal morphology changes

  • Track protein trafficking in live cells

What are the optimal conditions for immunofluorescence when studying VPS35?

For optimal immunofluorescence studies of VPS35:

• Cell Preparation: Plate cells (such as HAP1 wild-type and VPS35 knockout) in 96-well glass plates and incubate for 24 hours at 37°C with 5% CO₂ .

• Fixation and Permeabilization:

  • Fix cells with paraformaldehyde (PFA) in PBS for 15 minutes at room temperature

  • Wash 3 times with PBS

  • Permeabilize with PBS containing 0.1% Triton X-100 for 10 minutes

• Blocking: Block with PBS containing 5% BSA, 5% goat serum, and 0.01% Triton X-100 for 30 minutes at room temperature .

• Antibody Incubation:

  • Primary antibody: Incubate with VPS35 antibody in IF buffer (PBS, 5% BSA, 0.01% Triton X-100) overnight at 4°C

  • Secondary antibody: Use corresponding Alexa Fluor 555-conjugated secondary antibodies at 1.0 μg/mL for 1 hour at room temperature with DAPI counterstain

• Dilution Range: Use IF/ICC antibody dilutions between 1:200-1:800, optimizing for your specific cell type .

• Controls: For definitive validation, implement a mosaic approach by labeling wild-type and knockout cells with different fluorescent dyes and plating them together, allowing both cell types to be imaged in the same field of view. This reduces staining, imaging, and analysis bias .

How can researchers differentiate between VPS35 antibody specificity issues and experimental variables?

Differentiating between antibody specificity issues and experimental variables requires systematic controls and validation approaches:

• Knockout Controls: The gold standard for specificity validation is comparing signals between wild-type and knockout samples. A specific antibody will show signal only in wild-type samples .

• Multiple Antibody Validation: Use multiple antibodies targeting different epitopes of VPS35. Concordant results increase confidence in specificity .

• Positive Control Samples: Include samples known to express VPS35 (such as HepG2 cells, A549 cells, HAP1 cells, or HEK-293 cells) as positive controls .

• Batch Testing: When changing antibody lots, perform side-by-side comparisons with previous lots to identify potential manufacturing variations.

• Standardized Protocols: Implement standardized experimental protocols to minimize variability between experiments. This is particularly important when comparing results across different antibodies .

• Mosaic Approaches: For immunofluorescence, the mosaic approach (mixing labeled wild-type and knockout cells in the same well) eliminates variables in staining, imaging, and analysis conditions .

What are common troubleshooting strategies for poor VPS35 antibody performance?

When encountering poor VPS35 antibody performance, consider these troubleshooting strategies:

• Western Blot Issues:

  • For weak signals: Decrease antibody dilution (use more concentrated), increase protein loading, or extend exposure time

  • For multiple bands: Optimize blocking conditions, try different lysis buffers, or confirm protein degradation isn't occurring

  • For high background: Increase antibody dilution, extend blocking time, or use more stringent washing conditions

• Immunoprecipitation Problems:

  • For low recovery: Increase antibody amount (up to 4.0 μg for 1.0-3.0 mg of protein lysate), extend incubation time, or optimize binding conditions

  • For non-specific binding: Include additional washing steps or use more stringent washing buffers

• Immunofluorescence Challenges:

  • For weak staining: Optimize antibody concentration within the 1:200-1:800 range

  • For high background: Extend blocking time, increase antibody dilution, or add additional washes

  • For non-specific staining: Compare with knockout controls and optimize permeabilization conditions

• Sample-Specific Issues:

  • Different cell lines may require different optimal antibody dilutions

  • Tissue samples may require specific antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0 for IHC)

How should researchers interpret contradictory results when studying VPS35 across different experimental platforms?

When interpreting contradictory results across different experimental platforms:

• Consider Application-Specific Performance: An antibody that performs well in Western blot may not necessarily perform well in immunofluorescence. Each application requires different epitope accessibility and antibody characteristics .

• Evaluate Cell Type Differences: VPS35 expression levels and protein interactions may vary between cell types, potentially affecting antibody performance. HAP1, HepG2, A549, and HEK-293 cells have all been validated for VPS35 detection but may show differences .

• Assess Protocol Variables: Different lysis buffers, fixation methods, or antigen retrieval protocols can dramatically affect results. Standardize these elements when comparing across platforms .

• Cross-Validate with Multiple Techniques: When possible, verify findings using multiple techniques (WB, IP, IF) to build confidence in results that are consistent across platforms.

• Antibody Validation Status: Review the validation data for each antibody in the specific application where contradictions occur. Some antibodies may lack rigorous validation in certain applications .

• Knockout Controls: Implement knockout controls across all platforms to definitively determine specificity in each experimental context .

How can VPS35 antibodies be utilized to explore emerging connections to neurodegeneration mechanisms?

VPS35 antibodies offer powerful tools to explore neurodegeneration mechanisms through:

• Protein Interaction Studies: Use co-immunoprecipitation with VPS35 antibodies to identify novel interaction partners in neuronal cells, potentially revealing new therapeutic targets .

• Endosomal Dysfunction Analysis: Employ immunofluorescence to visualize alterations in endosomal morphology and VPS35 localization in disease models. Changes in subcellular distribution may provide insights into disease mechanisms .

• Retromer Complex Integrity Assessment: Study how VPS35 mutations or deficiency impacts the formation and stability of the retromer complex. Research shows that VPS35 downregulation leads to decreased levels of VPS26 and VPS29, affecting the entire complex .

• APP Processing Investigation: Use VPS35 antibodies to explore the relationship between retromer dysfunction and APP processing. Studies demonstrate that VPS35 deficiency increases steady-state APP levels and Aβ1-40 peptide production, directly linking retromer function to Alzheimer's pathology .

• Autophagy Pathway Connections: Investigate VPS35's role in autophagy by examining LC3 immunoreactivity in VPS35-deficient cells, potentially revealing connections between endosomal sorting and autophagy in neurodegeneration .

What methodological advances are enhancing the specificity and utility of VPS35 antibodies in research?

Recent methodological advances improving VPS35 antibody research include:

• Standardized Validation Approaches: The scientific community is implementing rigorous validation protocols using knockout controls to definitively establish antibody specificity. This systematic approach allows researchers to identify high-performing antibodies with confidence .

• Mosaic Imaging Strategies: The mosaic approach, where wild-type and knockout cells are differentially labeled and imaged in the same field of view, represents a significant advancement in reducing experimental bias during immunofluorescence studies .

• Open Science Principles: Recent research emphasizes delivering high-quality data to the scientific community based on Open Science principles, enabling researchers to independently interpret characterization data and select appropriate antibodies for their specific needs .

• Cross-Platform Validation: Comprehensive screening of antibodies across multiple applications (WB, IP, IF) provides researchers with a complete performance profile, facilitating informed antibody selection .

• Quantitative Performance Metrics: Establishing clear performance thresholds (e.g., 1.5-fold higher signal in wild-type vs. knockout cells for immunofluorescence) provides objective criteria for evaluating antibody quality .